Opdivo for Non-Small Cell Lung Cancer – Details


( Last Updated : August 15, 2016)
Generic Name:
Nivolumab
Project Status:
Complete
Therapeutic Area:
Metastatic non small cell lung cancer
Manufacturer:
Bristol-Myers Squibb Canada
Brand Name:
Opdivo
Project Line:
Reimbursement Review
Project Number:
PC0069-000
NOC Date:

Details


Strength:
40mg/4mL and 100mg/10mL vials
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer
Funding Request:
For the treatment of patients with advanced or metastatic non-small cell lung cancer who progressed on or after chemotherapy
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Bristol-Myers Squibb Canada
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Funding Request:
For the treatment of patients with advanced or metastatic non-small cell lung cancer who progressed on or after chemotherapy
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.